Presenter: Wen-Ching Lan Date: 2018/10/17

Slides:



Advertisements
Similar presentations
Managing anticoagulation in atrial fibrillation Dr Katy Rice June 2011.
Advertisements

Is low-dose Aspirin use associated with a reduced risk of colorectal cancer ? a QResearch primary care database analysis Prof Richard Logan, Dr Yana Vinogradova,
COHORH STUDY A research paper on BMJ. What is cohort study? Investigates from exposure to outcome, in a group of patients without, or with appropriate.
Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Abstract: WEABO205. HIV infection was associated with an increased risk of hip fracture,
Chapter 2: Identification and Care of Patients With CKD 2014 ANNUAL DATA REPORT VOLUME 1: CHRONIC KIDNEY DISEASE.
1 25th ECCMID , Munich, Germany Magnitude of bacteremia predicts one-year mortality Kim O. Gradel 1, Henrik C. Schønheyder 1,2, Mette Søgaard 1,
Surveillance of Heart Diseases and Stroke Using Centers for Medicare and Medicaid (CMS) Data: A Researcher’s Perspective Judith H. Lichtman, PhD MPH Associate.
PREDICTING STROKE IN ADULTS WITH NON-RHEUMATIC ATRIAL FIBRILLATION: SYSTEMATIC REVIEW OF VALIDATION OF CHADS 2 CLINICAL PREDICTION RULE (Preliminary results)
Public Health. CVDDiabetesCancer Antibiotic Resistance.
Improving the utility of comorbidity records Retha Steenkamp UK Renal Registry.
Global Variations in the 1-year Rates of Death and Stroke in Patients Presenting to the Emergency Department with Atrial Fibrillation Results from the.
The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]
A Claims Database Approach to Evaluating Cardiovascular Safety of ADHD Medications A. J. Allen, M.D., Ph.D. Child Psychiatrist, Pharmacologist Global Medical.
Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and.
ResultsIntroduction Atrial Fibrillation (AF) affects 1.2% 1 of the population and 10% of those over the age of 75 2 It is the commonest arrhythmia in primary.
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.
R4 문정락 / IC prof. 김진배 Lancet Haematol 2015;2: e150–59.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. Benefit of Anticoagulation Unlikely in Patients With Atrial.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.
2016 Annual Data Report, Vol 2, ESRD, Ch 5
R. Papani, A. G. Duarte, Y-L. Lin, G. Sharma
Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.
Presenter: Meng-Jiun Chiou 5Sep2017
2016 Annual Data Report, Vol 2, ESRD, Ch 6
Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study Kirchgesner J, et al. Gut 2017;0:1–8.
Copyright © 2014 American Medical Association. All rights reserved.
Patient populations by study group figure 10
Date:2017/10/03 Presenter: Wen-Ching Lan
Screening and diagnosis of AF and stratifying stroke risk
Chapter 2: Identification and Care of Patients With CKD
Mortality rates in incident ESRD patients figure 9
Lynn Josephs, David Culliford, Matthew Johnson, Mike Thomas
Volume 1: Chronic Kidney Disease
No evidence that AF type significantly impacts stroke risk
Quitting smoking after diagnosis of lung, bladder or upper aerodigestive tract (UAT) cancer: is it supported in primary care and does it improve prognosis?
Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal  Gregory.
Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.
Presenter: Wen-Ching Lan Date: 2018/05/09
Am J Kidney Dis Presenter: Wen-Ching Lan Date: 2018/01/03
Cohort study of preoperative blood pressure and risk of 30-day mortality after elective non-cardiac surgery  S. Venkatesan, P.R. Myles, H.J. Manning,
Presenter: Wen-Ching Lan Date: 2018/08/01
Volume 2: End-Stage Renal Disease Chapter 4: Hospitalization
Chapter 2: Pharmacological cholesterol-lowering treatment in adults
Chapter 4: Cardiovascular Disease in Patients with CKD
Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients  Jiacong Luo, MD, MS, MPH, Donna E.
Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.
Chronic kidney disease and cause-specific hospitalisation: a matched cohort study using primary and secondary care patient data by Masao Iwagami, Ben Caplin,
CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation  Walid Saliba, MD, MPH, Gad Rennert,
Annals of Internal Medicine • Vol. 167 No. 12 • 19 December 2017
The Research Question Aims
Chapter 2: Identification and Care of Patients with CKD
Living With an Older Person Dying From Cancer, Lung Disease, or Dementia: Health Outcomes From a General Practice Cohort Study  Elizabeth L. Sampson,
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of individual participant data from randomised trials 
Fig 6.1 Frequency of ischaemic heart disease in incident patients
External Validation of Existing Stroke Risk Models
Volume 145, Issue 1, Pages (January 2014)
Chronic kidney disease and cause-specific hospitalisation: a matched cohort study using primary and secondary care patient data by Masao Iwagami, Ben Caplin,
Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.
Efficacy and safety outcomes with NOAC compared with warfarin in NOAC patients with 14 457 years of risk and 49 418 warfarin patients with 75 747.
Evaluation of risk stratification schemes for ischaemic stroke and bleeding in patients with atrial fibrillation: the Swedish Atrial Fibrillation.
Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation.
Characteristics of 21,484 Patients With MI Who Survived for >30 Days After Discharge, by Calendar Year - Part I Soko Setoguchi, et al. J Am Coll Cardiol.
Volume 80, Issue 12, Pages (December 2011)
Low/moderate intensity statins High intensity statins
Figure 8. Stroke prevention strategy in patients with AF
Figure 2. Associations of comorbidities with PD in elderly participants in the multivariate regression analysis. The multivariate Cox proportional-hazards.
Low/moderate intensity statins High intensity statins
Chapter 2: Identification and Care of Patients with CKD
The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.
A – Demographic, Anthropometric and Clinical correlates of plasma NT-proBNP levels stratified by race: Multivariable Regression Results (Multivariable.
Presentation transcript:

Presenter: Wen-Ching Lan Date: 2018/10/17 Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies. Nicola J Adderley, Krishnarajah Nirantharakumar, Tom Marshall. BMJ 2018 Presenter: Wen-Ching Lan Date: 2018/10/17

Introduction Atrial fibrillation is the most common sustained cardiac arrhythmia and is associated with a fivefold increase in risk of stroke. Treatment with anticoagulants reduces the risk by about two thirds. Patients in whom atrial fibrillation is considered resolved might in fact have paroxysmal or persistent subtypes, or atrial fibrillation that might recur. 1

Objectives To determine rates of stroke or transient ischaemic attack (TIA) and all cause mortality in patients with a diagnosis of “resolved” atrial fibrillation compared to patients with unresolved atrial fibrillation and without atrial fibrillation. 2

Methods Data source We extracted datasets from The Health Improvement Network (THIN), a database of electronic primary care records from UK general practices using Vision software. THIN comprises coded data on patient characteristics, diagnoses, prescriptions, consultations, and investigations. 3

Methods Study design Adults aged 18 years or more and registered for at least 365 days before the census date were eligible for inclusion. stroke or TIA (primary outcome) and all cause mortality (secondary outcome) The study period was 1 January 2000 to 15 May 2016. The exposure was a clinical code of “atrial fibrillation resolved. The index date was the coding date for resolved atrial fibrillation plus 180 days. End date(patient left dataset or transferred out, death, study end date) or event date. 4

Methods Analysis Frequency of resolved atrial fibrillation χ2 test to calculate P values for trends over time. Incidence of stroke or TIA and mortality χ2 / t tests Poisson regression sensitivity analysis The Nelson-Aalen cumulative hazard function subgroup analysis 5

Methods Definitions of variables clinical code→ AF, paroxysmal AF, resolved AF, stroke, TIA(ischaemic stroke, haemorrhagic stroke) Heart failure, ischaemic heart disease, diabetes, hypertension THIN demography file→ BMI, Smoking status, Alcohol consumption, ethnicity (×1.210 if black) eGFR=186×(creatinine/88.4)-1.154×age-0.203×(0.742 if female) Charlson comorbidity index score CHA2DS2-VASc scores Current statin or anticoagulant (warfarin, parenteral anticoagulants, other vitamin K antagonists, and novel oral anticoagulants. )→ 90 days before the index date 6

Methods Missing data Variables were complete except for Townsend score, smoking status, drinking status, BMI, and eGFR. this assumed missingness was not associated with the outcome. We carried out a sensitivity analysis using multiple imputation (10 imputations, chained equations) to replace missing data; this made no difference to the results. 7

Results AF=atrial fibrillation; BMI=body mass index; eGFR=estimated glomerular filtration rate. *Absence of a record of current smoker was taken to indicate patient was not a current smoker. 99.0% of patients with atrial fibrillation resolved, 99.3% with atrial fibrillation and 96.5% without atrial fibrillation had a recorded smoking code. 8

Results 9

Results Fig 2 | Unadjusted Nelson-Aalen cumulative hazard estimates for stroke or transient ischaemic attack (TIA) in patients with resolved atrial fibrillation versus unresolved atrial fibrillation; mortality in patients with resolved atrial fibrillation versus unresolved atrial fibrillation; stroke or TIA in patients with resolved atrial fibrillation versus no atrial fibrillation; mortality in patients with resolved atrial fibrillation versus no atrial fibrillation (see supplementary figure 1 for adjusted cumulative hazard estimates)

11

12

Strengths / limitations large general practice database that is generalisable to the UK population and comprises routine clinical data used in decision making by general practitioners. Limitations Coded recording, Ethnicity, Townsend scores of may not accurately Some patients receiving anticoagulants might not have been identified if the treatment was managed entirely in secondary care, death is a competing risk. 13

Conclusion Patients with resolved atrial fibrillation remain at higher risk of stroke or TIA than patients without atrial fibrillation. The risk is increased even in those in whom recurrent atrial fibrillation is not documented. Guidelines should be updated to advocate continued use of anticoagulants in patients with resolved atrial fibrillation. 14

Thanks for listening.

Methods CCI score Disease 1 peripheral vascular disease, ulcer, chronic obstructive pulmonary disease or respiratory disease, connective tissue disease, dementia, heart failure or coronary heart disease, diabetes, mild liver disease, and myocardial infarction 2 cancer of the digestive, respiratory, or genitourinary tract, leukaemia, lymphoma, cancer of the lip, bone, or skin cancer, hemiplegia, and renal disease or chronic kidney disease 3 moderate to severe liver disease 6 metastatic cancer and HIV/AIDS CHA2DS2-VASc scores Disease/factor 1 congestive heart failure, hypertension, diabetes, vascular disease, age 65- 74 years, and female (if another risk factor was present, otherwise 0) 2 age ≥75. each defined by a clinical code recorded ever before index date. As we excluded patients with a history of stroke or TIA, 2 points were not added for these events. As patients with a history of stroke or TIA were excluded 1 point was not added for these events.